Alnylam Pharmaceuticals (NASDAQ:ALNY) Given New $375.00 Price Target at JPMorgan Chase & Co.

Alnylam Pharmaceuticals (NASDAQ:ALNY) had its price objective cut by equities researchers at JPMorgan Chase & Co. from $400.00 to $375.00 in a research report issued on Friday,Benzinga reports. The brokerage currently has an “overweight” rating on the biopharmaceutical company’s stock. JPMorgan Chase & Co.‘s price objective indicates a potential upside of 84.63% from the company’s current price.

ALNY has been the topic of several other research reports. Morgan Stanley cut their price objective on Alnylam Pharmaceuticals from $400.00 to $300.00 and set an “equal weight” rating on the stock in a research note on Friday. Weiss Ratings raised shares of Alnylam Pharmaceuticals from a “sell (d+)” rating to a “hold (c-)” rating in a report on Monday, May 4th. Royal Bank Of Canada reduced their target price on shares of Alnylam Pharmaceuticals from $450.00 to $445.00 and set an “outperform” rating for the company in a research note on Friday, May 1st. Bank of America lowered their price target on Alnylam Pharmaceuticals from $460.00 to $410.00 and set a “buy” rating on the stock in a report on Tuesday, July 14th. Finally, Stifel Nicolaus cut their price objective on shares of Alnylam Pharmaceuticals from $444.00 to $318.00 and set a “buy” rating on the stock in a research report on Friday. Two investment analysts have rated the stock with a Strong Buy rating, eighteen have issued a Buy rating and six have issued a Hold rating to the company. Based on data from MarketBeat.com, the company presently has a consensus rating of “Moderate Buy” and an average price target of $418.48.

Alnylam Pharmaceuticals Stock Down 1.2%

NASDAQ ALNY traded down $2.38 during trading hours on Friday, reaching $203.10. 2,668,101 shares of the company traded hands, compared to its average volume of 1,369,454. Alnylam Pharmaceuticals has a 12 month low of $197.81 and a 12 month high of $495.55. The company has a current ratio of 3.13, a quick ratio of 3.06 and a debt-to-equity ratio of 0.94. The stock has a market capitalization of $27.12 billion, a PE ratio of 55.56 and a beta of 0.27. The company has a 50 day moving average of $289.80 and a two-hundred day moving average of $312.07.

Alnylam Pharmaceuticals (NASDAQ:ALNY) last released its earnings results on Thursday, April 30th. The biopharmaceutical company reported $1.99 earnings per share for the quarter, topping the consensus estimate of $0.87 by $1.12. The company had revenue of $1.17 billion during the quarter, compared to the consensus estimate of $1.12 billion. Alnylam Pharmaceuticals had a net margin of 11.72% and a return on equity of 85.76%. The company’s revenue was up 96.4% on a year-over-year basis. During the same quarter in the previous year, the firm earned ($0.44) EPS. As a group, equities analysts expect that Alnylam Pharmaceuticals will post 7.35 earnings per share for the current year.

Insider Activity at Alnylam Pharmaceuticals

In related news, Director David E. I. Pyott sold 3,830 shares of the firm’s stock in a transaction on Monday, June 1st. The stock was sold at an average price of $299.18, for a total value of $1,145,859.40. Following the completion of the transaction, the director directly owned 1,582 shares of the company’s stock, valued at $473,302.76. This trade represents a 70.77% decrease in their ownership of the stock. The sale was disclosed in a document filed with the Securities & Exchange Commission, which is available through this hyperlink. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan. Insiders own 0.86% of the company’s stock.

Institutional Investors Weigh In On Alnylam Pharmaceuticals

Several institutional investors and hedge funds have recently bought and sold shares of ALNY. First Horizon Corp lifted its position in shares of Alnylam Pharmaceuticals by 20.7% in the 4th quarter. First Horizon Corp now owns 163 shares of the biopharmaceutical company’s stock worth $65,000 after purchasing an additional 28 shares during the period. Yousif Capital Management LLC boosted its position in shares of Alnylam Pharmaceuticals by 1.8% in the 4th quarter. Yousif Capital Management LLC now owns 1,676 shares of the biopharmaceutical company’s stock worth $666,000 after purchasing an additional 29 shares in the last quarter. Daiwa Securities Group Inc. boosted its position in shares of Alnylam Pharmaceuticals by 0.3% in the 2nd quarter. Daiwa Securities Group Inc. now owns 12,941 shares of the biopharmaceutical company’s stock worth $4,220,000 after purchasing an additional 35 shares in the last quarter. Golden State Wealth Management LLC grew its stake in shares of Alnylam Pharmaceuticals by 100.0% in the 4th quarter. Golden State Wealth Management LLC now owns 72 shares of the biopharmaceutical company’s stock worth $29,000 after buying an additional 36 shares during the last quarter. Finally, Coldstream Capital Management Inc. grew its stake in shares of Alnylam Pharmaceuticals by 2.4% in the 3rd quarter. Coldstream Capital Management Inc. now owns 1,640 shares of the biopharmaceutical company’s stock worth $748,000 after buying an additional 38 shares during the last quarter. Institutional investors own 92.97% of the company’s stock.

Key Headlines Impacting Alnylam Pharmaceuticals

Here are the key news stories impacting Alnylam Pharmaceuticals this week:

• Positive Sentiment: Several analysts retained bullish ratings despite reducing their targets. Oppenheimer lowered its target to $350 while maintaining “outperform,” Stifel cut its target to $318 while keeping a “buy” rating, Needham reduced its target to $357 with a “buy” rating, and Chardan reaffirmed “buy” with a $425 target. These targets imply considerable potential upside if Alnylam’s growth outlook stabilizes. Analyst price-target updates
• Neutral Sentiment: Alnylam reported second-quarter adjusted earnings of $1.84 per share, up from $0.32 a year earlier, while revenue increased 66.9% to $1.29 billion. However, reported revenue was below the $1.32 billion consensus estimate, and earnings estimates vary by data provider. Alnylam second-quarter earnings report
• Negative Sentiment: The main pressure came from a reduction to 2026 product-sales guidance and commentary that second-line Amvuttra demand is normalizing. Investors viewed the weaker ATTR outlook as outweighing record Amvuttra quarterly sales, prompting concerns about the pace and durability of future growth. Alnylam lowers 2026 outlook
• Negative Sentiment: Shareholder-rights law firms announced securities-fraud investigations following the selloff. The announcements may add reputational and legal overhang, although they do not establish wrongdoing by Alnylam. Securities-fraud investigation announcement

About Alnylam Pharmaceuticals

Alnylam Pharmaceuticals, Inc (NASDAQ: ALNY) is a biopharmaceutical company focused on the discovery, development and commercialization of RNA interference (RNAi) therapeutics. Founded to translate the scientific discovery of RNAi into new medicines, Alnylam applies small interfering RNA (siRNA) technology to silence disease-causing genes. The company develops therapies designed to provide durable disease modification by targeting underlying genetic drivers across a range of rare and more prevalent conditions.

Alnylam has advanced multiple siRNA-based products into commercialization, initially using lipid nanoparticle delivery and more recently employing GalNAc-conjugate chemistry to enable targeted delivery to the liver with subcutaneous dosing.